Patent 8642558 was granted and assigned to Henry Ford Health System on February, 2014 by the United States Patent and Trademark Office.
Methods, systems and compositions comprising novel peptidomimetics are disclosed that can be used to inhibit calpain and, more specifically, to treat tissue damage caused by pathologic activation of calpains.